Fennec Pharmaceuticals (FENC) Income from Non-Controlling Interests (2011 - 2019)
Fennec Pharmaceuticals (FENC) posted Income from Non-Controlling Interests of $17000.0 for Q2 2019, up 41.67% on a QoQ basis from $12000.0 in Q1 2019.
Fennec Pharmaceuticals (FENC) Income from Non-Controlling Interests (2011 - 2019) Analysis & Trends
Fennec Pharmaceuticals' Income from Non-Controlling Interests history runs 3 years deep, the most recent figure standing at $17000.0 for Q2 2019.
- Quarterly Income from Non-Controlling Interests changed N/A year-over-year to $17000.0 in Q2 2019, while the trailing twelve-month figure through Dec 2012 was $66.0 million (changed 0.0% YoY) and the FY2012 annual result came in at $66.0 million, changed 0.0% from the prior year.
- Income from Non-Controlling Interests was $17000.0 for Q2 2019 at Fennec Pharmaceuticals, up from $12000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $17000.0 in Q2 2019 and bottomed at $12000.0 in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.73 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.60 Bn | 467.81 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.34 Bn | 115.09 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.14 Bn | 61.39 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.79 Bn | 62.79 Bn | - | - |
| 8 | Argenx Se | 56.19 Bn | 51.00 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | - |
| 10 | Fennec Pharmaceuticals | 295.63 Mn | 258.84 Mn | 12.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 17,000.00 |
| Mar 31, 2019 | 12,000.00 |
| Dec 31, 2012 | 65.95 Mn |
| Dec 31, 2011 | 65.95 Mn |